Why a stomach effect can reach the pill
GLP-1 medicines slow how fast the stomach passes its contents on to the intestine. A tablet swallowed at the same time can therefore be absorbed later and, for a while, less sharply. For most medicines this matters little, but a contraceptive pill depends on reaching enough hormone in the blood, and the Mounjaro® label asks for monitoring of oral medicines that depend on reaching a threshold level to work [1].
The Mounjaro® and Zepbound® labels explain that the delay in stomach emptying with tirzepatide is greatest after the first dose and fades with later doses [1][2]; the EU document adds that the effect on other oral medicines is most pronounced when treatment begins [9]. That is why the US advice focuses on the weeks right after starting and right after each dose increase, rather than on the whole course of treatment. A broader look at other oral medicines is in the article on GLP-1s and oral medication absorption.
The documents side by side
| Document | What was measured | Result | What the document says |
|---|---|---|---|
| Mounjaro®, Zepbound®, US label 7.2, 8.3, 12.3 [1][2] | Ethinyl estradiol and norgestimate pill with one 5 mg dose | Peaks down 55–66%, total exposure down 20–23%, peak 2.5–4.5 h later | For 4 weeks from the start and from each dose step: a method not taken by mouth, or a barrier alongside the pill |
| Zepbound®, Canadian monograph 7 and 9.4 [13] | Same study | Peaks down 55–66%, exposure down 16–23% | Same 4-week advice as the US |
| Mounjaro®, EU SmPC 4.5 [9] | Same study | Same figures | Not considered clinically relevant; no change to the pill required |
| Foundayo™, US label 7.3, 8.3 [3] | Not tested in a clinical trial | Not available | Same advice over 30-day windows; effective contraception throughout |
| Ozempic®, US label 7.2, 12.3 [4] | Ethinylestradiol and levonorgestrel at semaglutide 1 mg | No dose adjustment needed | Caution with oral medicines in general |
| Wegovy®, Rybelsus®, US label 12.3 [5][6] | Same hormones with semaglutide tablets | No clinically significant change | No specific contraceptive advice |
| Wegovy®, EU SmPC 4.5 [10] | Same hormones with semaglutide | Levonorgestrel exposure up 20%, peaks unchanged | Not expected to reduce the pill’s effect |
| Saxenda®, US label 12.3; EU SmPC 4.5 [7][12] | Same hormones with liraglutide | Peaks down 12–13%, levonorgestrel exposure up 18%, peaks 1.5 h later | Contraceptive effect expected to be unaffected |
| Trulicity®, US label 7.1; EU SmPC 4.5 [8][11] | Norgestimate and ethinyl estradiol with dulaglutide 1.5 mg | Peaks down 26% and 13%, total exposure unchanged | Not clinically relevant; no change to the pill required |
The tirzepatide windows in detail
Both Mounjaro® and Zepbound® carry the same counselling point in sections 7.2, 8.3 and 17. During the first four weeks of treatment, and for four weeks after every step up in dose, people relying on an oral hormonal contraceptive are directed either to a method that is not taken by mouth or to a barrier method used in addition to the pill [1][2]. The labels add that hormonal contraceptives given another way are not expected to be affected.
The numbers come from a clinical pharmacology study in which a combined pill was given with a single 5 mg dose. Peak levels of ethinyl estradiol, norgestimate and its active form norelgestromin fell by 59%, 66% and 55%, overall exposure by 20% to 23%, and the peaks arrived 2.5 to 4.5 hours later [1]. The same section shows the effect fading with paracetamol (acetaminophen), a marker of stomach emptying: a first 5 mg dose halved its peak, yet by week 4 there was no meaningful effect [1]. No study measured whether pregnancies happened, which is why the labels turn the figures into a precaution rather than a prediction for any one person.
Why the European document reads it differently
The EU Mounjaro® product information reports the same reductions after a single dose, then states that they are not considered clinically relevant and that no dose adjustment of oral contraceptives is required [9]. It still asks clinicians to watch oral medicines with a narrow therapeutic index, such as warfarin, at the start of treatment and after each dose increase, and section 4.6 recommends contraception for women who could become pregnant [9].
Neither document is wrong; regulators can draw different conclusions from the same pharmacology data. Which advice applies depends on where your medicine was prescribed and on your prescriber’s view. If you hold a US or Canadian label, the four-week windows are what it says.
Foundayo: the same idea over 30 days
Foundayo™ (orforglipron) is a GLP-1 medicine taken as a daily tablet. Its label notes that its effect on pill absorption has not been tested in a clinical trial, but because delayed stomach emptying can affect oral medicines, it gives the same advice as the tirzepatide labels over 30-day windows: after starting, and after each dose increase (sections 7.3, 8.3 and 17) [3]. Like tirzepatide, its slowing of the stomach is largest after the first dose [3].
The Foundayo™ label also asks women who could become pregnant to use effective contraception throughout treatment, based on animal studies that suggest a possible risk to a fetus [3]. Orforglipron interacts with some other medicines through liver enzymes, a separate topic covered in the article on Foundayo™.
What the semaglutide, liraglutide and dulaglutide documents report
- Ozempic®: in clinical pharmacology studies at semaglutide 1 mg, a pill containing ethinylestradiol and levonorgestrel needed no dose adjustment, though section 7.2 still asks for caution with oral medicines in general [4].
- Wegovy® and Rybelsus®: section 12.3 lists ethinyl estradiol and levonorgestrel among drugs showing no clinically significant change when taken with semaglutide tablets [5][6]. The EU Wegovy® document found a 20% rise in levonorgestrel exposure and no change in peaks, and does not expect the pill to work less well [10].
- Saxenda®: liraglutide lowered the peak levels of ethinylestradiol and levonorgestrel by 12% and 13%, did not change overall ethinylestradiol exposure, raised levonorgestrel exposure by 18% and delayed both peaks by 1.5 hours [7]. The EU document expects the contraceptive effect to be unaffected [12].
- Trulicity®: the US label says dulaglutide 1.5 mg did not change absorption of the tested oral medicines to a clinically relevant degree, without naming the pill in its text [8]. The EU document does: peaks of norelgestromin and ethinyl estradiol fell by 26% and 13%, total exposure did not change, and no change to the pill is required [11].
- None of these documents carries the backup windows found in the tirzepatide and orforglipron labels.
Vomiting, diarrhea and the pill
There is a second route to a less reliable pill that has nothing to do with stomach emptying. MedlinePlus says that vomiting or diarrhea can make a combined pill work less well and asks you to contact your doctor about what to do; a backup method may be advised for a time [14]. Nausea, vomiting and diarrhea are among the most common side effects in the GLP-1 labels, and the Mounjaro® label notes that most reports came during dose escalation [1][2].
The GLP-1 labels do not say how to handle a pill after vomiting. That is a question for your pharmacist or the clinician who prescribed the pill, using the instructions for your specific brand.
If pregnancy is possible or planned
Contraception questions often sit next to pregnancy questions. The Zepbound® and Wegovy® labels say to stop the medicine once a pregnancy is recognised, and the semaglutide labels ask for a gap of at least two months before a planned pregnancy [2][5]. The EU Mounjaro® and Wegovy® documents recommend contraception for women who could become pregnant while on treatment [9][10]. The pregnancy article compares every label.
The counselling sections of labels such as Mounjaro® ask you to tell your healthcare provider if you are pregnant or plan to be [1]. MedlinePlus asks pill users who notice signs of pregnancy, such as nausea, vomiting or breast tenderness, to call their doctor and take a pregnancy test [14]; on a GLP-1 medicine nausea is common, so a test is the clearer guide.
Ozempic®, Wegovy®, Rybelsus® and Saxenda® are registered trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound® and Trulicity® are registered trademarks and Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly and Company.
When to get help
The signs and contact information below come from this article’s sourced guidance.